Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

Press Releases

Alexion to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 2, 2018
HTML PDF
Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
December 26, 2017
HTML PDF
Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
December 20, 2017
HTML PDF
Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
December 11, 2017
HTML PDF
Alexion and Halozyme Enter License Agreement for ENHANZE Technology
December 7, 2017
HTML PDF
Alexion to Present at the Citi 2017 Global Healthcare Conference
November 27, 2017
HTML PDF
Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
November 9, 2017
HTML PDF
Alexion Appoints Francois Nader, M.D. to its Board of Directors
November 8, 2017
HTML PDF
Alexion Receives New Japanese Patent for Soliris® (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
November 6, 2017
HTML PDF
New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma® (sebelipase alfa)
November 3, 2017
HTML PDF